Rett Syndrome Research Trust partners with Narrativa to bring AI Automation to the Clinical Trial Research Process

LOS ANGELES, November 1, 2023 – Focused on revolutionizing regulatory documentation and reporting for clinical trials, Rett Syndrome Research Trust (RSRT) is bringing together artificial intelligence, data analytics, insights and state-of-the-art technology to super-charge it’s clinical research process through a joint partnership with Narrativa, a leading AI (artificial intelligence) company in the life sciences industry. 

RSRT and Narrativa are launching a new clinical research process that will transform data collected from clinical trials and market research into knowledge utilizing Narrativa’s proprietary generative AI content platform. The natural language generation (NLG) and natural language processing (NLP)-enabled platform will assist the RSRT research team with the automation of Tables, Listings, and Figures (TLFs), and the summarization of research across multiple studies that precisely monitors the symptoms and well-being of patients impacted by Rett Syndrome. With automated insights from this data, the non-profit RSRT will be further empowering the patients and families directly impacted by this rare disease, helping them to find more resources and support.

“The Life Sciences industry is at a precipice. Utilizing the advancements of artificial intelligence to automate the clinical trial regulatory documentation and research processes will bring drugs and deeper insights to market faster. This will help more patients and ultimately save more lives. AI and humans are always better together, and we want every workforce to feel better equipped with our AI software as their writing and research assistant,” says Narrativa President, Jennifer Bittinger. 

Based in Los Angeles, Narrativa currently services a variety of organizations in the life sciences, such as pharma sponsors, CROs (contract research organizations), biotech research companies, and even regulators. Narrativa’s AI-writing assistant platform uses advanced natural language generation (NLG) and natural language processing (NLP) as it runs through millions of data points from multiple sources to generate readable and comprehensible regulatory reports that increase accuracy, and drastically reduce the time and cost to create critical (and laborious) documents and reporting.

RSRT and Narrativa will launch  their new AI-automation solution for clinical research this quarter to better support the lives of those  patients and families impacted by Rett Syndrome. 

About Narrativa

Narrativa is an internationally recognized generative AI content company that believes people and artificial intelligence are better together. Through its proprietary content automation platform, teams of all types and sizes are empowered to build and deploy smart composition, business intelligence reporting, and process optimization content solutions for internal and external audiences alike. 

Its tech stack, consisting of data extraction, data analysis, natural language processing (NLP), and natural language generation (NLG) tools, all seamlessly work together to produce content quickly and at scale. In this way, Narrativa supports the growth of businesses across a variety of industries, while also saving them both time and money. Accelerate the potential with Narrativa.

Contact us to learn more about our solutions!

About Rett Syndrome Research Trust

RSRT is a nonprofit organization with a highly personal and urgent mission: achieving a cure for Rett syndrome and related disorders caused by defects in the MECP2 gene. Since its founding in 2008, RSRT has awarded more funds than any other Rett organization in the world, to leading scientists pursuing targeted research on Rett. RSRT funds and spearheads global scientific and clinical activities advancing the most promising curative approaches. To date, every biopharmaceutical company pursuing a cure for Rett syndrome is doing so because they leveraged discoveries and resources incubated with RSRT funding. To learn more, please visit www.reverserett.org.